Search

Jun 7, 2024
X4 Pharma's CEO on the recent launch of XOLREMDI for WHIM Syndrome and CXCR4 inhibition more broadly for additional indications
Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4...